Bry-Air unveils P80x for pharma industry

IMT News Desk
IMT News Desk
· 2 min read

The product unveiling took place at India Expo Centre, Greater Noida during PMEC Expo 2025 in presence of the pharma industry leaders

Bry-Air marked the grand unveiling of its latest innovation, the P80x dehumidifier, at PMEC Expo 2025. The product unveiling took place at India Expo Centre, Greater Noida in presence of the pharma industry leaders.

Powered by the revolutionary MIRACLE Next-Gen Rotor based on MOF (Metal-Organic Frameworks) technology, it marks a significant leap in dehumidification technology. P80x has been designed to break free from Silica Gel, which has been used as a primary desiccant for dehumidification in the pharma industry for more than three decades.

The product surpasses the Silica Gel–based systems, as the breakthrough innovation is proficient at achieving unmatched efficiency and sustainability. Power-packed with the salient feature of high performance, it drives 25% extra performance against the traditional counterpart of silica gel rotors, translating to an exponential reduction in the operational cost. It facilitates a lower regeneration temperature of 60°C–80°C in comparison to the conventional 120°C–140°C, enabling a reduced regeneration temperature that promotes increased energy savings of more than 50% while ensuring system longevity.

By introducing P80x, Bry-Air reinforces its commitment to innovation that levels up the game for pharmaceutical production by delivering solutions that meet the compliance requirements of the industry.

Read Next

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya
News
June 5, 2026

Centre Reaffirms Commitment to Building Healthcare Infrastructure Across Northeast India; Nadda Inaugurates Super-Specialty Hospital in Meghalaya

Union Health Minister J P Nadda on Thursday declared that the Central Government remains firmly committed to strengthening healthcare infrastructure across the Northeast and ensuring that advanced medical services reach people living in remote and underserved areas of the region. Nadda made these remarks while inaugurating ARHI Hospital in Meghalaya’s Ri-Bhoi district- a new super-specialty […]
Article by: IMT News Desk
Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today
News
June 5, 2026

Hexagon Nutrition Raises Rs 41.66 Crore from Anchor Investors Ahead of Rs 139-Crore IPO Opening Today

Mumbai-based Hexagon Nutrition Ltd has mobilised Rs 41.66 crore from anchor investors ahead of its initial public offering (IPO), which opened for public subscription on June 5 and will remain open until June 9, 2026. According to a circular uploaded on BSE’s website, the company allotted a total of 92.57 lakh equity shares to anchor […]
Article by: IMT News Desk
Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval
News
June 5, 2026

Otsuka’s Voyxact Shows Kidney Function Preservation in Late-Stage IgAN Trial, Setting Stage for Full FDA Approval

Otsuka Pharmaceutical has reported that its approved kidney disease drug Voyxact (sibeprenlimab) preserved kidney function over 12 months in a late-stage clinical study, marking a significant milestone in the treatment of immunoglobulin A nephropathy (IgAN), a serious autoimmune condition that progressively damages the kidneys. In the Phase 3 VISIONARY trial involving 320 participants, patients who […]
Article by: IMT News Desk
Akums Receives European CEP Approval for Cefpodoxime Proxetil
News
June 4, 2026

Akums Receives European CEP Approval for Cefpodoxime Proxetil

Akums Drugs & Pharmaceuticals Ltd. has received a Certificate of Suitability (CEP) from the European Directorate for the Quality of Medicines & HealthCare (EDQM) for its active pharmaceutical ingredient (API), Cefpodoxime Proxetil. The CEP certification confirms that Akums’ manufacturing process and quality standards for Cefpodoxime Proxetil comply with the requirements of the European Pharmacopoeia. The […]
Article by: IMT News Desk